Glenmark Pharmaceuticals added 1.75% after the company announced launch of Nebzmart GFB Smartules and Glenmark Airz FB Smartules, the world's first nebulized, fixed-dose triple therapy for Chronic ...
If you’re one of the 35 million people living with a chronic lung disease in the United States, the form of treatment you receive can impact your health outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback